Направление

Инфраструктура и клиническая практика

Клеточные атласы, общедоступные наборы данных, лабораторные приборы и способы доставки терапевтических средств обеспечивают работу других подходов. Области также нужны специалисты, организации и пути внедрения в клиническую практику, которые превращают открытия в основу для дальнейшей работы.

Все направления

Иллюстрации созданы с помощью искусственного интеллекта (AI) и передают общую идею. Результаты исследований изложены в тексте со ссылками на источники.

Следующий вопрос

Сможет ли другая лаборатория воспроизвести результат и продолжить работу на его основе?

Данные исследованийОбщедоступный клеточный атлас

Проект Tabula Muris опубликовал общедоступный ресурс с данными более чем о 100,000 клетках из двадцати органов и тканей мыши. Он позволяет исследователям сравнивать типы клеток в разных частях организма, опираясь на единые справочные данные.

Что остаётся выяснить. Атлас служит инструментом исследования; сам по себе он лечебного действия не оказывает. Его ценность зависит от того, насколько новые эксперименты позволяют использовать и дополнять собранные данные.

Прочитать статьюSingle-cell transcriptomics of 20 mouse organs creates a Tabula MurisTabula Muris Consortium · Nature · 2018

Сравнение

Сравнение проектов с оценками

Проект▲	Обещанный эффект▲	Доказательства▲	Стадия▲	Самый весомый довод против▲
DTL	+0,5 года жизни	The evidence base is mostly product positioning: the DTL page claims coverage of 700+ longevity biotech companies, 3,100+ drug assets, 14 domains, continuous monitoring, reports, and traceable copilot answers.	Appears active as of 2026, with a live product page, contact/demo flow, custom-report offering, and a publicly announced strategic partnership with AND Capital Ventures.	The main failure mode is that DTL is mostly packaging: a marketing-led aggregation product without defensible data quality, differentiated insight, or measurable decision advantage over generic research workflows and incumbent intelligence platforms.
First Approval	+0,5 года жизни	The project-specific evidence base is mostly platform and competition copy.	The project looks pre-scale but active.	The failure case is straightforward: this may be mostly packaging around a familiar open-science problem without proving that researchers will change behavior.
NUS Academy for Healthy Longevity	+1,5 года жизни	The evidence base is credible for field-building and measurement, weaker for intervention efficacy.	Operational but early.	The project could stall as a well-branded but weakly validated platform if biomarker-guided personalization does not translate into robust human benefit, if single-arm multimodal studies remain too confounded to interpret, or if supplement- and partnership-driven narratives outpace regulation and evidence.
Pentara Brain Stride	+0,5 года жизни	There is relevant background evidence that optimized cognitive endpoints and enrichment strategies matter in Alzheimer's and preclinical AD studies, including longitudinal cohort analyses and endpoint-methodology work.	The project appears to be an operating company service rather than an early concept.	The project may amount to a strong specialist CRO-style service with good positioning but limited proof of differentiated outcomes.
R42 Group	+1,5 года жизни	The strongest project-specific evidence supports R42 as an active funder and venture platform, not as a validated scientific program.	Active but weakly validated.	R42 may also be mostly narrative.
Singularis: reforming the communication of scientific knowledge	The claimed effect could be meaningful: faster navigation of hypotheses, experiments, results, conclusions, and evidence than reading narrative papers.	There is a visible beta product page and a team-authored project description, plus field-context literature showing that linked research, continuous publishing, computable knowledge, and agent-native research artifacts are active areas.	Early stage and beta.	The project may stall because the hard part is not just graph technology but institutional adoption, annotation accuracy, and migration of legacy literature; without strong precision, clear user advantage, and integration into existing evaluation systems, it risks remaining an interesting beta visualization layer on top of papers rather than changing scientific communication.

Компании

Компании этого направления

Заявленные цели отражают то, чего компания обещает достичь. Независимое воспроизведение результатов показывает, что подтвердили другие исследователи. Сопоставляйте обе колонки: разрыв между ними показывает, насколько обещания опережают подтверждённые результаты.

Компания▲	Масштаб цели▲	Независимое воспроизведение▲	Стадия▲	Главный офис▲
Ani Biome ANI Biome builds autonomous intelligence for human biology and longevity medicine using multiomics, digital phenotyping, and physician-supervised intervention.	7	1	–	San Francisco, California
AVEA AVEA develops science-backed longevity supplements for energy, sleep, skin, gut, glucose metabolism, and healthy ageing.	6	2	–	Berlin, Germany
Healome Healome is an AI health coach to track and slow biological age.	6	1	–	Hyderabad, India
Humanity Inc Humanity is an app that monitors rate of aging and helps users identify actions to improve healthspan.	6	0	–	United Kingdom
Ichor Life Sciences Ichor Life Sciences is a pre-clinical CRO providing drug R&D services to biotechnology and pharmaceutical companies.	7	2	–	Syracuse, New York, United States
L-Nutra L-Nutra develops plant-based nutrition technology, including fasting mimicking diet programs, to support healthspan, longevity, and metabolic health.	5	3	–	Culver City, California, United States
Magnitude Biosciences Magnitude Biosciences provides customised C. elegans studies and whole-organism high-throughput screening for research areas including ageing, neurodegeneration, toxicity, and gut health.	6	4	–	United Kingdom
Minicircle Minicircle offers non-viral plasmid gene therapy for longevity, performance, wellness, and body-composition benefits.	7	1	–	–
OneSkin Technologies OneSkin develops topical OS-01 peptide products for healthy skin aging and cellular senescence reduction.	6	2	–	San Francisco, California, United States

Проекты

Проекты этого направления

Проект▲	Стадия▲	Самый веский аргумент против▲
Beat-FSHD Beat-FSHD appears to be a patient-facing FSHD support, education, advocacy, and news website rather than a research or therapeutic program.	Project status is difficult to rate highly from the provided evidence.	The project may simply be an underdeveloped or placeholder website with weak editorial controls and unclear ownership.
DTL DTL appears to be a UK-based longevity market-intelligence product from First Longevity / Longevity.Technology, positioned as an AI-enabled, structured data and analysis layer over longevity biotech companies, drug assets, and related signals such as trials, financing, IP, partnerships, and talent.	Appears active as of 2026, with a live product page, contact/demo flow, custom-report offering, and a publicly announced strategic partnership with AND Capital Ventures.	The main failure mode is that DTL is mostly packaging: a marketing-led aggregation product without defensible data quality, differentiated insight, or measurable decision advantage over generic research workflows and incumbent intelligence platforms.
First Approval First Approval appears to be an early-stage scientific data publishing platform for biology and longevity-adjacent research, centered on structured dataset annotation, decentralized/encrypted storage, customizable licensing, DOI-linked publication, and incentive mechanisms for sharing.	The project looks pre-scale but active.	The failure case is straightforward: this may be mostly packaging around a familiar open-science problem without proving that researchers will change behavior.
FuturVille FuturVille is a for-profit Canadian project positioning itself as a builder of "healthy longevity villages," with VulcanVille in Vulcan, Alberta presented as the first prototype: a 53-63 acre mixed-use site with 300+ dwelling units, wellness and retreat facilities, commercial space, and related development/investment offerings.	Early commercial development and branding stage.	The more likely failure mode is that FuturVille remains a promotional wellness-real-estate concept with overstated health claims, weak scientific grounding, limited execution capacity, and no credible evidence that its village model adds measurable healthy years beyond standard amenity-driven community living.
Gobal Health Span Extension Global Health Span Extension appears to be a Felix Platter-affiliated healthy-aging/healthspan initiative or consortium, but the direct project evidence is thin: the Felix Platter site mainly shows a navigation-level reference to a “Global Health Span Extension Consortium” rather than a substantive project description.	Project status is unclear from the direct Felix Platter evidence.	The main downside case is that this is more branding and consortium framing than demonstrated project substance: the direct evidence for the project itself is sparse, the strongest adjacent evidence is still only partially visible from titles/metadata in several cases, and even positive DO-HEALTH-style signals may prove modest, population-specific, or insufficient to justify broad claims about extending healthspan.
Healthspan Quest Healthspan Quest appears, on the available evidence, to be a Valley Christian Schools student team in the 2024-25 XPRIZE Healthspan competition rather than a validated longevity research program or venture.	Earliest reliable status is that Healthspan Quest was presented by Valley Christian Schools as a 2024-25 XPRIZE Healthspan team and reported as Top 100.	The more likely interpretation from current evidence is that Healthspan Quest is mainly a school-branded competition team with aspirational longevity language and little verifiable substance yet.
NUS Academy for Healthy Longevity The NUS Academy for Healthy Longevity appears to be a Singapore-based precision-geromedicine hub at NUS that combines clinical-trial infrastructure, biomarker-oriented research, education, and public-facing convening around healthy longevity.	Operational but early.	The project could stall as a well-branded but weakly validated platform if biomarker-guided personalization does not translate into robust human benefit, if single-arm multimodal studies remain too confounded to interpret, or if supplement- and partnership-driven narratives outpace regulation and evidence.
Pentara Brain Stride Pentara Brain Stride appears to be a clinical-trial biostatistics and data-integrity offering focused on neurodegenerative disease studies, especially regulatory-facing trial design, analysis, and fraud detection.	The project appears to be an operating company service rather than an early concept.	The project may amount to a strong specialist CRO-style service with good positioning but limited proof of differentiated outcomes.
R42 Group R42 Group appears to be a U.S.-based, founder-led venture platform and family-office-derived group centered on AI, biotech, and longevity, with an adjacent education/community arm (R42 Institute).	Active but weakly validated.	R42 may also be mostly narrative.
Singularis: reforming the communication of scientific knowledge Singularis is an early-stage scientific-knowledge platform that argues conventional papers are a bottleneck for both human readers and AI systems, and proposes converting papers into structured argumentation graphs and nanopublication-like units that link hypotheses, methods, results, conclusions, and evidence.	Early stage and beta.	The project may stall because the hard part is not just graph technology but institutional adoption, annotation accuracy, and migration of legacy literature; without strong precision, clear user advantage, and integration into existing evaluation systems, it risks remaining an interesting beta visualization layer on top of papers rather than changing scientific communication.
Team NovaVita Available evidence does not substantiate Team NovaVita as a distinct longevity project.	Status is unclear and low-confidence.	The more likely interpretation is identity mismatch: “Team NovaVita” appears to be a student leadership or branding label, while the longevity-related patent and PKU materials are generic field context with no verified connection to the project.

Люди

Люди этого направления

Хронология

События и даты

29 апр. 2024 г.Краудфандинг
Humanity Inc

Прогнозы

Прогнозы по этому направлению

Все прогнозы

В этом месяце

Последние сообщения

Все новости